Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Are Bullish on These Healthcare Stocks: Atai Beckley N.V. (ATAI), BridgeBio Oncology Therapeutics (BBOT)

Tipranks - Tipranks - Wed Mar 11, 6:10AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Atai Beckley N.V. (ATAI – Research Report), BridgeBio Oncology Therapeutics (BBOT – Research Report) and Vertex Pharmaceuticals (VRTX – Research Report) with bullish sentiments.

Claim 70% Off TipRanks Premium

Atai Beckley N.V. (ATAI)

Oppenheimer analyst Jay Olson maintained a Buy rating on Atai Beckley N.V. yesterday and set a price target of $16.00. The company’s shares closed last Monday at $3.89.

According to TipRanks.com, Olson is a 5-star analyst with an average return of 18.5% and a 46.6% success rate. Olson covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, Madrigal Pharmaceuticals, and Vertex Pharmaceuticals. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Atai Beckley N.V. with a $14.33 average price target, representing a 321.5% upside. In a report issued on February 26, Needham also maintained a Buy rating on the stock with a $14.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

BridgeBio Oncology Therapeutics (BBOT)

Morgan Stanley analyst Sean Laaman maintained a Buy rating on BridgeBio Oncology Therapeutics yesterday and set a price target of $18.00. The company’s shares closed last Monday at $10.31.

According to TipRanks.com, Laaman is a 5-star analyst with an average return of 11.5% and a 60.9% success rate. Laaman covers the Healthcare sector, focusing on stocks such as Contineum Therapeutics, Inc. Class A, ACADIA Pharmaceuticals, and Jazz Pharmaceuticals. ;'>

Currently, the analyst consensus on BridgeBio Oncology Therapeutics is a Strong Buy with an average price target of $25.38, representing a 142.2% upside. In a report issued on March 6, Stifel Nicolaus also maintained a Buy rating on the stock with a $23.00 price target.

Vertex Pharmaceuticals (VRTX)

UBS analyst Michael Yee maintained a Buy rating on Vertex Pharmaceuticals yesterday and set a price target of $545.00. The company’s shares closed last Monday at $460.87.

According to TipRanks.com, Yee is a 1-star analyst with an average return of -0.3% and a 42.8% success rate. Yee covers the Healthcare sector, focusing on stocks such as MBX Biosciences, Inc., Olema Pharmaceuticals, and Allogene Therapeutics. ;'>

Vertex Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $554.45, implying a 21.7% upside from current levels. In a report released today, Jefferies also initiated coverage with a Buy rating on the stock with a $580.00 price target.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).